Quick Facts

• Relief from: Seasonal allergic rhinitis (hay fever)
• Relief from: Perennial allergic rhinitis (year-round allergies)
• Helps manage: Nasal discomfort, sneezing, and runny nose
• Supports management of: Vasomotor rhinitis symptoms

---

Allergodil 0.05% (azelastine hydrochloride) nasal spray is a prescription treatment option used to address symptoms associated with allergic rhinitis. It is approved to provide relief from the symptoms of seasonal allergic rhinitis, commonly known as hay fever, and perennial allergic rhinitis, which involves year-round nasal discomfort. The medication may help reduce common signs of these conditions, such as sneezing, nasal itching, and an excessive runny nose (rhinorrhea).

This treatment is also indicated for the symptomatic management of vasomotor rhinitis in certain adult and adolescent patient groups. Vasomotor rhinitis is a non-allergic condition that can result in symptoms like nasal congestion, postnasal drip, and excessive mucus production. By addressing these core symptoms, the agent contributes to the overall management of these nasal conditions.

This medication is part of a therapeutic class designed to support the relief of allergy-related nasal symptoms.

Population Eligibility and Regulatory Restrictions

Official regulatory documents define strict criteria for who can and cannot use Allergodil 0.05% (azelastine hydrochloride nasal spray) based on age, physiological status, and known allergies. The use of this medicine is absolutely prohibited for any individual with a known hypersensitivity to azelastine hydrochloride or any other component of the formulation.

Eligibility is defined by minimum age thresholds. For seasonal allergic rhinitis (SAR), use is established for adults and children five years of age and older. The indication for vasomotor rhinitis (VAR), however, is restricted to adults and adolescents twelve years of age and older. Use is therefore not established in children below these specific age thresholds.

Conditional restrictions apply to several populations. Caution is formally required for patients with renal insufficiency due to the potential for increased systemic exposure of the medicine. Use is also restricted for populations who are pregnant or breastfeeding, where caution is recommended as azelastine is known to pass into human milk in small amounts. Additionally, regulatory information advises that concurrent use with alcohol or other Central Nervous System (CNS) depressants should be avoided due to the potential risk of compounded impairment.

Official Interaction Profile

The regulatory interaction profile for Azelastine 0.05% nasal spray is primarily characterized by a pharmacodynamic constraint concerning substances that affect the central nervous system.

• Central Nervous System (CNS) Depressants and Alcohol: Concurrent use with alcohol and other CNS Depressants, such as sedatives, should be avoided as stated in regulatory labeling. This is due to a documented risk of additive impairment of CNS performance and additional reductions in alertness.

Pharmacokinetic Findings

Specific pharmacokinetic (PK) interaction studies are documented, although regulators note their relevance to the low-systemic-exposure nasal spray is limited. Co-administration of high-dose oral Cimetidine officially resulted in a sim 65% increase in the mean plasma concentration of oral Azelastine. Conversely, regulatory studies with Erythromycin and Ranitidine failed to demonstrate a PK interaction.

Interaction-Related Restrictions

• Contraindicated Combinations: No medicinal products are listed as an absolute contraindication based solely on an interaction risk in the official labeling.
• Timing Rules: No mandatory timing-separation requirements are documented.
• Special Populations: The regulatory profile specifies that no data are available on interaction patterns in patients with hepatic or renal impairment for the nasal spray formulation.

Dual Mechanism: H₁ Antagonism and Mast Cell Stabilization

Azelastine operates through a combined mechanism by serving as a selective H₁-receptor antagonist while also acting as a mast cell stabilizer. This dual action enables the drug to intervene at two mechanistic points: directly blocking the effects of released histamine and concurrently inhibiting the further release of histamine and other inflammatory mediators from the mast cells. This coordinated approach results in the modulation of the allergic inflammatory pathway at the cellular and molecular level.

---

Modulation of Nasal Vascular and Sensory Pathways

By antagonizing H₁ receptors, Azelastine prevents histamine from activating its target receptors on endothelial cells and vascular smooth muscle. This molecular action results in the inhibition of histamine's effect on vascular permeability, thereby regulating fluid extravasation into the nasal tissue. Simultaneously, the blockade of H₁ receptors on sensory nerve endings diminishes the chemical stimulation of these fibers, which regulates the afferent nerve impulses originating from the nasal mucosa.

---

Mechanistic Limitation in Non-Allergic Conditions

The functionality of this mechanism is intrinsically linked to the dominance of the histamine-driven allergic cascade. The mechanism provides limited functional engagement when physiological responses are primarily driven by non-histaminergic factors, such as inflammatory mediators or pathways prevalent in non-allergic (vasomotor or irritant) rhinitis, underscoring the mechanistic specificity of Azelastine's targets.

Official Administration Guidelines

Allergodil 0.05% (azelastine hydrochloride) is provided as an aqueous metered-dose nasal spray solution and is approved for intranasal use only. Proper administration relies on a standardized schedule and specific procedural steps detailed in prescribing information.

---

Dosing Schedule and Frequency

Patient Group	Condition	Standard Dosing Regimen	Frequency
Adults & Adolescents (12 years and older)	Seasonal Allergic Rhinitis (SAR)	1 or 2 sprays per nostril	Twice daily
Adults & Adolescents (12 years and older)	Vasomotor Rhinitis (VMR)	2 sprays per nostril	Twice daily
Pediatric (5 to 11 years)	Seasonal Allergic Rhinitis (SAR)	1 spray per nostril	Twice daily

For some high-concentration formulations (0.15% strength), an alternative once daily regimen of two sprays per nostril may be used for adults and adolescents with SAR. Dosing recommendations may vary by region and formulation strength.

---

Procedural Instructions and Rules

• Priming: Before initial use, the spray pump must be primed by releasing a set number of sprays (e.g., 4 to 6 actuations) until a fine mist is observed. If the product has not been used for three or more days, it must be re-primed (e.g., 2 sprays).
• Administration: The bottle must be held vertically upright and the spray tip inserted into the nostril, aimed toward the back of the nose. Application is strictly limited to the intranasal route; official instructions caution against spraying the solution into the eyes.
• Missed Dose: If a dose is missed, it should be used as soon as the patient remembers, unless it is nearly time for the next scheduled dose. It is advised not to administer a double dose to compensate for the missed one.
• Use Duration: The medication is administered on an intermittent basis for seasonal allergic rhinitis, while use for perennial or vasomotor rhinitis is typically continuous.

These instructions collectively define the procedure for administering azelastine nasal spray to ensure the correct volume and dose are delivered.

Research Evidence / Overview of Studies

---

Efficacy in Chronic Rhinitis Management

Clinical trials have investigated the effect of the azelastine 0.05% nasal spray on symptoms associated with Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR). Research has examined whether use of the spray was associated with changes in key nasal symptoms, including sneezing, runny nose, and nasal congestion, often using total nasal symptom scores (TNSS).

Studies generally report a relatively fast onset of action following administration, often within 15 to 30 minutes, which is a factor assessed in patient preference studies. Findings also suggest that the spray may be effective in addressing nasal congestion, a symptom less consistently addressed by some oral antihistamines alone.

---

Comparison with Other Regimens

Controlled studies have compared azelastine nasal spray against placebo and other treatments, including intranasal corticosteroids (such as fluticasone or mometasone) and oral antihistamines, to examine symptom control.

Research has investigated whether the combination of azelastine with an intranasal corticosteroid (in a higher 0.1% or 0.15% strength) resulted in greater symptom improvement than either agent used alone, particularly for difficult-to-treat symptoms.

---

Safety Profile and Long-Term Use

Long-term studies in adults, extending up to six months, have investigated the safety profile of azelastine nasal spray. The most commonly reported events in trials have included a temporary bitter taste, headache, and somnolence (drowsiness). The incidence of these events was monitored closely in extended treatment periods. Studies have explored the drug's profile when used over several months to evaluate tolerability for patients with chronic rhinitis.

Common questions about Allergodil 0.05% (FAQ)

---

Q: Can you use Allergodil 0.05% if you are pregnant or breastfeeding?

Official regulatory information advises caution regarding the use of Allergodil 0.05% during pregnancy and while breastfeeding. Studies have indicated that Azelastine is known to pass into human milk in small amounts. Use of the medicine is considered appropriate only when the potential benefit is judged to justify the potential risks.

---

Q: Does Allergodil 0.05% help with allergy symptoms other than just a runny nose?

Regulatory information indicates that clinical trials have examined the effect of the nasal spray on a range of symptoms associated with Seasonal Allergic Rhinitis (SAR). These symptoms typically include sneezing and nasal congestion, in addition to a runny nose.

---

Q: Does Allergodil 0.05% help with sinus congestion or only nasal drip?

Studies have investigated the drug's effect on nasal congestion. Official evidence indicates that the nasal spray may be associated with changes in this symptom, alongside nasal drip. Research has specifically examined its effect on symptoms including congestion.

---

Q: How quickly does Allergodil 0.05% usually start to work?

Clinical trials generally report that the nasal spray has a relatively fast onset of action. Official information suggests symptom relief is often observed within 15 to 30 minutes following administration.

---

Q: Can I use Allergodil 0.05% if I have high blood pressure or a heart condition?

Official regulatory documents do not list high blood pressure or specific heart conditions as formal contraindications or specific warnings for the use of Azelastine nasal spray. Restrictions focus mainly on known allergies to the product and use with other Central Nervous System depressants.

---

Q: Is Allergodil 0.05% safe to use for a long period of time?

Long-term studies in adults have been conducted to investigate the profile of azelastine nasal spray, sometimes extending up to six months. These studies monitor the incidence of reported events over extended treatment periods to evaluate tolerability.

---

Q: Can Allergodil 0.05% be used for non-allergic rhinitis?

Official regulatory documents list Vasomotor Rhinitis (VMR) as an approved indication for use in eligible patients (adults and adolescents 12 years of age and older). VMR is a common type of non-allergic rhinitis.

---

Q: Can people with glaucoma safely use Allergodil 0.05%?

Official regulatory documents do not list glaucoma as a specific contraindication or special precaution for the nasal spray formulation. Cautions listed are primarily related to hypersensitivity and concurrent use with Central Nervous System depressants.

---

Q: Are there any common over-the-counter medicines that interact with Allergodil 0.05%?

Regulatory labeling states that concurrent use with alcohol and other Central Nervous System (CNS) Depressants should be avoided. This is due to a documented risk of additive impairment of CNS performance and reduced alertness. This includes some over-the-counter sleep aids or cold/flu medicines that may contain CNS-depressing ingredients.

---

Q: Can Allergodil 0.05% affect the sense of smell or taste permanently?

Bitter taste (dysgeusia) is listed as a very common side effect in clinical studies. Official safety information does not describe this or any related sense of smell or taste effect as permanent.

---

Q: Does the efficacy of Allergodil 0.05% decrease over time with continued use?

Regulatory and clinical trial reports confirm the use of the drug in long-term studies up to six months. Official documentation does not contain claims or findings indicating a decrease in effectiveness (tachyphylaxis) over this period.

---

Q: What is the difference between Allergodil 0.05% and a steroid nasal spray?

Allergodil 0.05% is classified as an H₁-receptor antagonist and mast cell stabilizer and does not contain steroids. Regulatory research has compared azelastine nasal spray against intranasal corticosteroids to examine differences in symptom control.

---

Q: Is the small amount absorbed systemically when using Allergodil 0.05%?

The spray is designed for local action, aiming to maximize concentration at the nasal site while minimizing systemic exposure. However, pharmacokinetic studies indicate that some small degree of systemic exposure does occur.

---

Q: Can I use Allergodil 0.05% if I have a history of seizures?

Regulatory warnings primarily focus on the additive impairment of Central Nervous System (CNS) performance when used with alcohol or other CNS depressants. Seizure disorders are not explicitly listed as a formal contraindication or special precaution in the official labeling.

---

Q: Is Allergodil 0.05% the same as Astelin?

Astelin is a specific brand name for Azelastine hydrochloride nasal spray. Allergodil 0.05% contains the same active ingredient, Azelastine hydrochloride, at the 0.05% concentration.

---

Q: What is the safety profile of Allergodil 0.05% compared to oral antihistamines?

Controlled studies have compared azelastine nasal spray against oral antihistamines to examine differences in symptom control and tolerability. For the nasal spray, the most commonly reported side effects in trials included bitter taste, headache, and somnolence (drowsiness).

---

Q: Is Allergodil 0.05% available without a prescription in some countries?

The regulatory status of azelastine nasal spray formulations, determining whether it is available by prescription or over-the-counter (OTC), is known to vary by country and specific product strength.

---

Q: Is it possible to become dependent on Allergodil 0.05% if used regularly?

Official regulatory warnings for azelastine nasal spray do not describe a risk of dependence or addiction. Dependence is typically a concern associated with prolonged use of certain nasal decongestant products.

---

Q: Does Allergodil 0.05% cause rebound congestion like other nasal sprays?

Rebound congestion, a phenomenon associated with prolonged use of nasal decongestant products, is not listed as a known or expected adverse reaction for Allergodil 0.05% in official regulatory documentation.

---

Q: Are there different concentrations of Allergodil available?

In addition to the 0.05% concentration, regulatory documentation mentions the existence of other azelastine nasal spray concentrations that may be approved in some regions for different dosing regimens or indications.

---

Q: Do I need to clean my nose before using Allergodil 0.05%?

While not a mandatory instruction in the official procedural rules, patient information often suggests gently blowing the nose beforehand. This is generally advised to help ensure the nostrils are clear prior to administration of the spray.

---

Q: Has Allergodil 0.05% been studied in the elderly population?

Official labeling notes that studies have investigated the effects of azelastine nasal spray in patients 65 years and older with rhinitis. It is also noted that elderly patients are more likely to have age-related organ issues which may require caution.

---

Q: Is there a link between Allergodil 0.05% and anxiety or mood changes?

Official adverse reaction reports include classification for Nervous System Disorders (e.g., somnolence, headache). However, official safety information does not list anxiety or mood changes as common or specifically noted side effects.

How to Store and Dispose of Allergodil 0.05%?

Regulatory documents define the required conditions for storing and disposing of Allergodil 0.05% (azelastine hydrochloride) nasal spray.

Official Storage Conditions

Requirement	Specification (Regulatory Basis)
Temperature	Store at Controlled Room Temperature (20 to 25 C / 68 to 77 F).
Protection	Must be protected from freezing, excess heat, and moisture.
Packaging	Keep the container tightly closed in its original packaging.
Stability	Discard any remaining contents six months after first opening.
Safety	Keep the product out of the sight and reach of children.

Official Disposal Requirements

Official guidelines state that the unused or expired product must not be thrown into wastewater (flushed down the toilet or sink). Disposal of non-flushable medicines should involve consulting a healthcare professional or following instructions to mix the product with an undesirable substance before placing it in household trash, where a drug take-back program is unavailable. These instructions are mandatory to ensure both product stability and safe environmental disposal.